BNET Industries
MedImmune Inc. is in the Business Services Industry
Latest News and Analysis
MedImmune CEO Quits AstraZeneca
By Ben Hirschler LONDON (Reuters UK) - David Mott, the head of AstraZeneca's AZN MedImmune unit, is to leave the group at the end of July, one year after selling his biotech business to the Anglo-Swedish drugmaker. An AstraZeneca spokesman said on Thursday Mott had decided...
Licensing Strategies After Medimmune: The Potential Impacts Of The Supreme Court Allowing Licensees
In MedImmune, the Supreme Court continues to assert its authority in patent law by allowing patent licensees to file declaratory judgments of patent invalidity and unenforceability against the licensors, even though the licensee is still paying royalties under a license. MedImmune may also indicate the Supreme Court's direction in future...
Additional Resources
DIREVO Receives Broad European Patent Protection for its Protease Optimization Platform
DIREVO Biotech AG, a world-wide leader inhigh throughput protein and strain engineering, announced today receipt ofnotice from the European Patent Office that the post-granting oppositionperiod had ended without a filed opposition against Patent Grant No. EP150411. This patent, entitled, "Process for Generating Sequence-SpecificProteases by Directed Evolution", broadly claims methods for...
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab in Patients with Acute Lymphoblastic Leukemia
BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTER antibody blinatumomab (MT103/MEDI-538) in patients with adult acute lymphoblastic leukemia ALL. Blinatumomab is a T cell...
Genentech Settles Dispute Related to Cabilly Patent
SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE: DNA) announced today that it has settled its patent litigation with MedImmune, Inc. involving the Cabilly patent (U.S. Patent No. 6,331,415), which is co-owned by Genentech and City of Hope and relates in part to methods of producing antibodies. Under...
MedImmune's Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
GAITHERSBURG, Md., June 6 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that the Montgomery County Chamber of Commerce has presented Brian Rosen, senior director, government affairs, with its 2008 Chairman's Award at the organization's 49th Annual Dinner held recently at the Bethesda North Marriott Hotel...
Hiring underway at Gaithersburg-based MedImmune
MedImmune Inc., of Gaithersburg, a biotechnology company focused on developing and manufacturing products to combat infectious disease, autoimmune disease and cancer, announced that it is looking to fill more than 800 jobs, mostly in research and development and clinical positions, by the end of the year, expanding its work force...
Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmune's biologics capabilities. "MedImmune...
Executives from Gartner, Cisco, CNET, MedImmune and Sodexo to Discuss Security and Compliance at the 6th Annual Qualys SaaS Security Conference
SAN FRANCISCO -- Qualys[R], Inc., the leading provider of on demand IT security risk and compliance management solutions, today announced its lineup of top security professionals who will be presenting at the 2008 Qualys Security Conference. This annual event, in its sixth year, is focused on best practices and solutions...
Genaera Corporation Announces Initiatives to Conserve Resources to Continue Development Efforts
- Cash for Operations through Second Quarter 2009 - PLYMOUTH MEETING, Pa., May 8 /PRNewswire-FirstCall/ -- Genaera Corporation today announced plans that will enable the Company to continue development efforts over the next 12 months for its trodusquemine (MSI-1436) type 2 diabetes and obesity program,...
Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC's 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Presenters include David M. Mott from MedImmune Inc., Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company, Federico Goodsaid, Ph.D from the FDA, and Mark Ratner from FDC_Windhover WESTBOROUGH, Mass., May 7 /PRNewswire/ -- IBC Life Sciences announced the keynote line up for the 13th Annual Drug Discovery...
MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
GAITHERSBURG, Md., May 6 /PRNewswire/ -- MedImmune today announced that it has enhanced its leadership team to guide the company's expanded product pipeline in the United States and abroad as well as the core scientific research that underpins this development. Jacqueline Hall has been appointed global vice president, product...
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
Retrospective Chart Review in 10 Geographic Regions throughout the United States Presented at Pediatric Academic Societies PAS Annual Meeting HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of SynagisR palivizumab as a preventive...
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies Annual Meeting
- In Clinical Trial, Motavizumab Reduced Hospitalizations Due to Respiratory Syncytial Virus by 83 Percent Compared to Placebo - HONOLULU, May 4 /PRNewswire/ -- MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody MAb that...
Fourteen Abstracts Featuring MedImmune's Influenza and RSV Therapeutic Areas to Be Presented at Pediatric Academic Societies Annual Meeting
Results Provide Insights into Infectious Disease Prevention in Children GAITHERSBURG, Md., April 28 /PRNewswire/ -- MedImmune today announced that researchers will present results from a host of studies in pediatric infectious disease, featuring FluMistR (Influenza Virus Vaccine Live, Intranasal) as well as SynagisR palivizumab and emerging RSV...
OVATION Appoints Samuel Yonren, M.D. as Vice President, Patient Safety
DEERFIELD, Ill. -- OVATION Pharmaceuticals, Inc. announced today that it has named Samuel Yonren, M.D. MRCP as Vice President, Patient Safety with responsibility for global drug safety for all OVATION products. A career drug safety physician with broad international pharmaceutical industry experience, Yonren joins OVATION from MedImmune in...
REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. BCI, a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system CNS diseases, announced today that it raised an additional $20 million in an extension...
BrainCells Inc. Expands Series B Financing to $50 Million
SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. BCI, a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system CNS diseases, announced today that it raised an additional $20 million in an extension...
Gaithersburg-based MedImmune drug advances
MedImmune Inc., of Gaithersburg, a biotechnology company focused on developing and manufacturing products to combat infectious disease, autoimmune disease and cancer, announced the start of two new clinical trials as part of its efforts to develop CAT-354, an antibody that MedImmune sees as a potential treatment for patients with asthma....
IPS Vaccine Alliance Reaches Enrollment Milestone
ATLANTA -- Integrated Physician Solutions IPS, a wholly-owned subsidiary of Orion HealthCorp, Inc., today announced that the total physician membership of its Vaccine Purchasing Alliance now exceeds 750 physicians nationwide. The IPS Vaccine Purchasing Alliance is an open access group purchasing organization that offers its members discounted pricing...
- Next »
- page 1 of 42
- « Previous
Sort byClose
MedImmune Inc. Company Info
NAICS Code
Research and Development in the Social Sciences and Humanities: 541720
